Company Profile For Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based research and development biopharmaceutical company. The Company focuses its activities on the areas of antibacterials, antifungals and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea Pharmaceutica's late-stage product portfolio includes treatments for resistant bacterial infections, systemic fungal infections, and skin diseases. The portfolio comprises two commercialized drugs (Toctino and ZEFTERA/Zevtera), one investigational drug in clinical phase III (isavuconazole) as well as a number of early-stage programs. Its Isavuconazole compound, which is a broad-spectrum antifungal for the treatment of severe invasive fungal infect. Ceftobiprole is an antibiotic effective against certain life-threatening drug-resistant bacteria and Alitretinoin is an oral retinoid for the treatment of patients with chronic hand dermatitis. The Company has subsidiaries in North America, Europe and China.

BRIEF: For the six months ended 30 June 2009, Basilea Pharmaceutica AG's total revenue increased from SF5.2M to SF12M. Net loss for the period decreased 2% to SF66.6M. Total revenue reflects an increase in demand for the Company's products and services. Lower net loss for the period reflects an increase in other financial result. Basilea Pharmaceutica is a Switzerland-based research and development biopharmaceutical company.

Basilea Pharmaceutica AG
Grenzacherstrasse 487
Basel     4058
P: +4161.6061111
F: +4161.6061112

300